Institute of Biomedical Research Corp. Logo

Institute of Biomedical Research Corp.

MRES

(1.8)
Stock Price

0,01 USD

-358.07% ROA

131.12% ROE

-0.09x PER

Market Cap.

11.145.674,00 USD

-116.41% DER

0% Yield

0% NPM

Institute of Biomedical Research Corp. Stock Analysis

Institute of Biomedical Research Corp. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Institute of Biomedical Research Corp. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (131.12%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

With a remarkably low PBV ratio (-0.14x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a minimal amount of debt (-116%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

5 ROA

The stock's ROA (-358.07%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Institute of Biomedical Research Corp. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Institute of Biomedical Research Corp. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Institute of Biomedical Research Corp. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Institute of Biomedical Research Corp. Revenue
Year Revenue Growth
2003 0
2004 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Institute of Biomedical Research Corp. Research and Development Expenses
Year Research and Development Expenses Growth
2003 0
2004 0 0%
2006 92.900 100%
2007 0 0%
2008 147.782 100%
2009 20.657 -615.41%
2010 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Institute of Biomedical Research Corp. General and Administrative Expenses
Year General and Administrative Expenses Growth
2003 0
2004 0 0%
2006 0 0%
2007 0 0%
2008 3.877.958 100%
2009 374.136 -936.51%
2010 20.724 -1705.33%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Institute of Biomedical Research Corp. EBITDA
Year EBITDA Growth
2003 -11.474
2004 -14.577 21.29%
2006 -95.032 84.66%
2007 -819.506 88.4%
2008 -5.320.255 84.6%
2009 -398.781 -1234.13%
2010 -20.724 -1824.25%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Institute of Biomedical Research Corp. Gross Profit
Year Gross Profit Growth
2003 0
2004 0 0%
2006 0 0%
2007 -786.105 100%
2008 -1.250.000 37.11%
2009 0 0%
2010 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Institute of Biomedical Research Corp. Net Profit
Year Net Profit Growth
2003 -14.733
2004 -20.140 26.85%
2006 -176.881 88.61%
2007 -690.299 74.38%
2008 -5.367.187 87.14%
2009 -443.288 -1110.77%
2010 -222.752 -99.01%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Institute of Biomedical Research Corp. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2003 0
2004 0 0%
2006 0 0%
2007 0 0%
2008 -2 100%
2009 0 0%
2010 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Institute of Biomedical Research Corp. Free Cashflow
Year Free Cashflow Growth
2003 -13.944
2004 -23.276 40.09%
2006 -154.865 84.97%
2007 -23.279 -565.26%
2008 -205.525 88.67%
2009 -413.920 50.35%
2010 -5.181 -7889.19%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Institute of Biomedical Research Corp. Operating Cashflow
Year Operating Cashflow Growth
2003 -13.944
2004 -23.276 40.09%
2006 -154.865 84.97%
2007 -23.279 -565.26%
2008 -98.256 76.31%
2009 -406.617 75.84%
2010 -5.181 -7748.23%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Institute of Biomedical Research Corp. Capital Expenditure
Year Capital Expenditure Growth
2003 0
2004 0 0%
2006 0 0%
2007 0 0%
2008 107.269 100%
2009 7.303 -1368.83%
2010 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Institute of Biomedical Research Corp. Equity
Year Equity Growth
2003 -66.011
2004 -91.006 27.47%
2006 -116.022 21.56%
2007 -21.680 -435.16%
2008 -82.422 73.7%
2009 -71.812 -14.77%
2010 193.273 137.16%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Institute of Biomedical Research Corp. Assets
Year Assets Growth
2003 0
2004 0 0%
2006 111.186 100%
2007 0 0%
2008 103.979 100%
2009 77.610 -33.98%
2010 654.604 88.14%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Institute of Biomedical Research Corp. Liabilities
Year Liabilities Growth
2003 66.011
2004 91.006 27.47%
2006 227.208 59.95%
2007 21.680 -948.01%
2008 186.401 88.37%
2009 149.422 -24.75%
2010 461.331 67.61%

Institute of Biomedical Research Corp. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.05
Price to Earning Ratio
-0.09x
Price To Sales Ratio
0x
POCF Ratio
-0.11
PFCF Ratio
-46.58
Price to Book Ratio
-0.07
EV to Sales
0
EV Over EBITDA
-48.29
EV to Operating CashFlow
-49.82
EV to FreeCashFlow
-48.26
Earnings Yield
-10.95
FreeCashFlow Yield
-0.02
Market Cap
0,01 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.27
Graham NetNet
-0.08

Income Statement Metrics

Net Income per Share
-0.05
Income Quality
0.85
ROE
1.31
Return On Assets
-3.58
Return On Capital Employed
0.76
Net Income per EBT
1
EBT Per Ebit
1.04
Ebit per Revenue
0
Effective Tax Rate
-0.09

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.04
Free CashFlow per Share
-0.05
Capex to Operating CashFlow
-0.03
Capex to Revenue
0
Capex to Depreciation
0.33
Return on Invested Capital
-5.02
Return on Tangible Assets
-3.58
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,06
Tangible Book Value per Share
-0.06
Shareholders Equity per Share
-0.06
Interest Debt per Share
0.08
Debt to Equity
-1.16
Debt to Assets
5.26
Net Debt to EBITDA
-1.68
Current Ratio
0
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-359813
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.04

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Institute of Biomedical Research Corp. Dividends
Year Dividends Growth

Institute of Biomedical Research Corp. Profile

About Institute of Biomedical Research Corp.

Institute of Biomedical Research Corp. provides biomedical research and analytical services in Montenegro and internationally. Its services include regulatory control of industrial activities and products; scientific surveillance of the living environment; research and development of biomedical products and technologies; regulatory evaluation and certification of biomedical products; fundamental scientific research; and development of new diagnostic methods and experimental medical treatments. The company also researchers and develops new biomedical and food products; provides programs for graduate research studies in biomedical and environmental fields; offers two channel analog NMS, digital muscle stimulator, digital TENS, interferential, elite combination, portable four channel digital, portable ultra sound, and other healthcare devices; and provides photon red light for beauty, electric pain relief products, microcurrent electrical nerve stimulators, and high volt pulsed stimulators. In addition, it develops and commercializes microbicidal agents; disinfectant products; bandages for large burns, hard surface disinfection, microbicidal treatment of fabrics and textile products, insecticides against bed bugs and other textile goods, microbicidal towels, and mouthwash products; Purilair, an appliance that sterilizes compressed air circulating within medical instruments; colloidal silver and electro medical devices; and BioStim INF that is used for edema reduction, pain relief, and total treatment. Further, the company provides quality control, regulatory, healthcare, environmental services, environmental analysis, building decontamination, and environmental protection and management services; and regulatory certifications of new biomedical products. Institute of Biomedical Research Corp. was founded in 2010 and is based in Podgorica, Montenegro with a representative office in Montreal, Canada.

CEO
Dr. Drasko D. Pekovic
Employee
0
Address
Ljubljanska bb
Podgorica, 81000

Institute of Biomedical Research Corp. Executives & BODs

Institute of Biomedical Research Corp. Executives & BODs
# Name Age
1 Dr. Drasko D. Pekovic
Founder, Chairman of the Board, Chief Executive Officer & President
70
2 Mr. Teodor Burtea
Director & Member of Scientific Council
70
3 Mr. Victor Lange
Chief Executive Officer of M2MMA
70

Institute of Biomedical Research Corp. Competitors